X0c9d8dde.aec7.4a95.b86c.da554465897b
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.440
- MYC_TARGETS_V1+0.370
- E2F_TARGETS+0.330
- G2M_CHECKPOINT+0.290
- OXIDATIVE_PHOSPHORYLATION+0.250
- DNA_REPAIR+0.240
- SPERMATOGENESIS+0.120
- ANGIOGENESIS+0.100
- UNFOLDED_PROTEIN_RESPONSE+0.100
- KRAS_SIGNALING_DN+0.080
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.430
- INTERFERON_ALPHA_RESPONSE-0.420
- INTERFERON_GAMMA_RESPONSE-0.380
- INFLAMMATORY_RESPONSE-0.370
- KRAS_SIGNALING_UP-0.350
- COMPLEMENT-0.340
- ALLOGRAFT_REJECTION-0.330
- IL6_JAK_STAT3_SIGNALING-0.330
- TGF_BETA_SIGNALING-0.330
- IL2_STAT5_SIGNALING-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_R439VVPK | medulloblastoma | — | 0.900 |
| 2 | s_150324_3a | EPN | Posterior Fossa EPN | 0.897 |
| 3 | TCGA-NC-A5HH-01A-11R-A26W-07 | — | cohortMD1 | 0.892 |
| 4 | X97abcebb.f885.4eca.9af4.91a0adb97578 | — | cohortMD1 | 0.891 |
| 5 | AUR-AG0N-TTM1-A-1-1-R-A743-41 | — | E | 0.886 |
| 6 | SRR8518260 | — | A | 0.885 |
| 7 | C3L-00993 | — | cohortSQ1 | 0.883 |
| 8 | MNG392 | — | — | 0.883 |
| 9 | BS_JZRM1S3T | medulloblastoma | — | 0.882 |
| 10 | 1b572d35-f98e-4389-b234-a2591a74d7a8 | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.440 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.370 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.290 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.240 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.100 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.100 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.070 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.040 | Inavolisib | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |